Experience

Neumora Therapeutics – $250.1 Million IPO

September 15, 2023

Cooley advised the underwriters on the $250.1 million initial public offering of Neumora Therapeutics, a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed.

Read more

Related contacts

Charlie Kim
Partner, San Diego
Kristin VanderPas
Partner, San Francisco
David Peinsipp
Partner, San Francisco
Denny Won
Partner, San Francisco
Grady Chang
Associate, Santa Monica
Madison (JJ) Meng
Associate, San Francisco
Peter A. Haddad
Associate, San Diego
Heidi Ausman
Senior Paralegal, San Diego
Lila Hope
Partner, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Mika Reiner Mayer
Partner, Palo Alto
Barbara Mirza
Partner, Santa Monica
Phil Mitchell
Partner, New York
Jennifer Raab
Partner, Palo Alto
Dr. Madhuri Roy
Partner, Palo Alto
Erica Russell
Associate, San Francisco
Randy Sabett
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Francis Wheeler
Senior Counsel, Colorado
Mark Windfeld-Hansen
Senior Counsel, Palo Alto

Related Practices & Industries

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.